As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib

<div>The difference in survival with combination therapy of TACE and sorafenib after dividing patients into 3 groups based on diarrhea and HFSR-response. Group 1, complete responders; Group 2, partial responders; Group 3, non-responders.</div>

Canadian Journal of Gastroenterology and Hepatology

fig1

Figure 1

Figure 1: As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib 

Figure 1 | As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib 